Lilly and Enron
The Securities & Exchange Commission has subpoenaed Lilly to provide information about an energy management services contract it had with Enron. Lilly characterizes the subpoena as unsurprising, given the scope of the ongoing investigation about Enron's accounting practices, and says it is cooperating. Lilly says it has not been contacted by any other government entity to provide information about Enron contracts. The contract was terminated in July...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”